Combined blocking of PD-1/PD-L1 and CTLA-4 negative co-stimulatory pathway can make tumor-specific T cells that would otherwise be inactivated continue to expand and play an effective role, thus transforming the tumor microenvironment from an inhibitory state to an immune response state (11). The gene discussed is PDCD1; the disease is neoplasm.